Astellas Pharma Inc 2019 AR2
The report highlights Astellas Pharma Inc.'s progress during the fiscal year ended March 31, 2019, which marked the first year of its Strategic Plan 2018. The company achieved increases in both revenue and profit, with core operating profit and core profit reaching all-time highs. Key achievements included the successful launches of XOSPATA in Japan and the U.S., and steady sales growth of XTANDI and mirabegron. Astellas also advanced its Focus Area approach, investing in cell therapy and acquiring Potenza Therapeutics and Quethera. Additionally, the company launched the Astellas Global Health Foundation to improve access to health in underserved global communities.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2019
Type: AR2
Pages: 112
Back to company
Astellas Pharma Inc
Annual Report
The report highlights Astellas Pharma Inc.'s progress during the fiscal year ended March 31, 2019, which marked the first year of its Strategic Plan 2018. The company achieved increases in both revenue and profit, with core operating profit and core profit reaching all-time highs. Key achievements included the successful launches of XOSPATA in Japan and the U.S., and steady sales growth of XTANDI and mirabegron. Astellas also advanced its Focus Area approach, investing in cell therapy and acquiring Potenza Therapeutics and Quethera. Additionally, the company launched the Astellas Global Health Foundation to improve access to health in underserved global communities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Published
Nov 29, 2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees